Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations research hub

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

This study is testing a new tablet, S241656, for people with certain types of cancer linked to specific gene changes (like KRAS or BRAF). Researchers want to find the safest dose, see how well it works, and understand its side effects, both alone and with other cancer treatments.